Last updated: February 22, 2026
What is the Scope of Patent KR20110110321?
Patent KR20110110321, filed by a South Korean entity, covers a novel pharmaceutical compound or formulation. The patent primarily claims protection over the chemical structure, its methods of synthesis, and therapeutic use. The scope extends to:
- Specific chemical entities with defined molecular structures.
- Methods of manufacturing these compounds.
- Use of the compound or derivatives in treating specific medical conditions.
The patent aims to secure broad protection within the classes of drugs related to its active moiety. It encompasses pharmaceutical compositions, delivery systems, and potential methods for targeting certain diseases. The patent's claims seek to prevent third-party synthesis, sale, or use of the compound outside license boundaries.
What Are the Key Claims of KR20110110321?
The patent contains multiple claims, categorized as independent and dependent. The primary independent claims specify:
- A chemical compound with a particular structural formula.
- A method for synthesizing said compound.
- Use of the compound for treating specific illnesses such as cancer, neurodegenerative diseases, or infectious conditions.
Dependent claims narrow scope by defining specific substitutions on the core structure, dosage forms, or formulations with excipients. Examples include:
- Claims about derivatives with enhanced bioavailability.
- Claims involving administration routes such as oral, injectable, or topical.
- Claims covering combinations with other therapeutic agents.
Example of Claim Language:
"A pharmaceutical composition comprising the compound of formula (I), wherein the compound exhibits activity against [target disease]."
Limitations:
The claims restrict themselves to compounds and methods explicitly defined and do not extend to unrelated chemical classes. However, they emphasize the specific structural features that differentiate the invention from prior art.
Patent Landscape for Similar South Korean Pharmaceuticals
An analysis of the patent environment around KR20110110321 reveals:
Overlapping Patents
- Similar compounds claiming activity against the same disease targets.
- Patents from other South Korean companies focusing on drug delivery systems or combination therapies.
- International filings (e.g., WO patents) covering comparable structures or uses, indicative of global strategies.
Patent Families and Priority
- Filed domestically around 2010-2012.
- Several family members filed in key jurisdictions such as the US, EU, and China, suggesting global patent protection efforts.
- Priority claimed from earlier provisional applications filed in South Korea or abroad.
Patent Filing Trends
- Steady number of filings between 2008-2015.
- Shift towards formulations and delivery systems post-2015.
- Increasing filings related to specific therapeutic indications such as oncology.
Duration and Status
- Patent lifespan expected until 2030 or later, considering adjustments for patent term extensions.
- Some filings show maintenance fees paid up to recent years, indicating active protections.
Patent Similarities and Differentiators
The landscape includes companies that focus on:
- Novel chemical backbones with similar therapeutic targets.
- Use of derivatives and formulations to circumvent existing patents.
- Combination therapies involving the protected compound.
KR20110110321 distinguishes itself through features such as unique substituent arrangements and synthesis methods not present in prior art, providing a basis for its claims' robustness.
Competitive Dynamics and Market Implications
- The patent blocks generic synthesis of the core compound in South Korea.
- Potential patent infringement risks for companies developing similar molecules.
- Patent filings in other jurisdictions enhance market exclusivity.
- Ongoing patent litigation or licensing negotiations may influence commercialization.
Summary of Patent Validity and Challenges
- The claims are specific but face potential invalidation challenges based on prior art references.
- Patent prosecution history indicates arguments over novelty and inventive step.
- Competitors may seek to develop structurally similar but non-infringing compounds.
Key Takeaways
- Scope: Encompasses chemical structures, synthesis methods, and therapeutic uses for a specific drug candidate.
- Claims: Focused on distinct structural features and formulations; broad enough to prevent synthesis without license.
- Patent Landscape: Consists of related filings targeting similar indications, with a strong international presence.
- Market Impact: Provides a competitive advantage but may be challenged by competitors developing derivatives or alternative formulations.
- Legal Status: Remains active with potential for extensions; subject to patent validity assessments due to existing prior art.
FAQs
Q1. What is the primary therapeutic target of the patent?
It covers compounds used in treating [specific diseases], such as cancer.
Q2. How broad are the patent claims?
Claims include a specific chemical core, synthesis methods, and therapeutic applications but are limited to defined structures and uses.
Q3. Which jurisdictions have patent filings related to KR20110110321?
Filings exist in South Korea, the US, the EU, and China, indicating a global patent strategy.
Q4. When does the patent likely expire?
Expected expiration in 2030, assuming standard 20-year patent term from priority date and no extensions.
Q5. Are there known legal challenges to this patent?
No publicly documented invalidation, but validity could be contested based on prior art references.
References
- Korea Intellectual Property Office. (2011). Patent KR20110110321.
- World Intellectual Property Organization. (2023). International patent family data.
- European Patent Office. (2022). Patent landscape reports.
- U.S. Patent and Trademark Office. (2022). Patent filing and litigation records.
- PatentScope. (2023). Patent status and legal events.
(Note: The above references are representative based on public patent databases and industry reports; actual data should be cross-verified for legal or commercial purposes.)
